THU041 Clinical Improvements In Patients With Cushing’s Disease Treated With Osilodrostat According To Urinary And Late-night Salivary Cortisol Levels: Pooled Analysis From LINC 3 And LINC 4

Disclosure: B.M. Biller: Consulting Fee; Self; HRA Pharmaceuticals, Recordati Rare Diseases, Sparrow, Xeris Pharmaceuticals (Strongbridge). Research Investigator; Self; served on the LINC 3 steering committee. M. Fleseriu: Consulting Fee; Self; HRA Pharmaceuticals, Recordati Rare Diseases, Sparrow,...

Descripción completa

Detalles Bibliográficos
Autores principales: Biller, Beverly M K, Fleseriu, Maria, Pivonello, Rosario, Feelders, Richard, Gadelha, Mônica, Lacroix, André, Witek, Przemysław, Heaney, Anthony P, Piacentini, Andrea, Pedroncelli, Alberto M, Newell-Price, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Neuroendocrinology And Pituitary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554895/
http://dx.doi.org/10.1210/jendso/bvad114.1121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554895/
http://dx.doi.org/10.1210/jendso/bvad114.1121

Ejemplares similares